Skip to main content

08-02-2017 | Children | Book chapter | Article

14. Islet Cell Transplantation

Authors: Antonio Bruni, Michael McCall, A. M. James Shapiro

Publisher: Springer Berlin Heidelberg



For a subset of patients with complicated Type I Diabetes Mellitus (T1DM), islet transplantation has become a well-established treatment modality. Before 2000, fewer than 9% of islet transplant recipient maintained insulin independence for greater than one year. The improvements resulting from the Edmonton Protocol have led to high rates of one-year insulin independence, and together with an international collaboration, propagated the expansion of clinical islet transplantation centers worldwide. In spite of the continued success of clinical islet transplantation, a number of limitations with this therapy remain, including the requirement for lifelong immunosuppression with the associated side effects. While islet transplantation is currently generally reserved for adults with T1DM with severe hypoglycemia or glycemic lability, we herein consider the possibility of its application to the pediatric population, moving this therapy one day from a treatment for some to a potential cure for all.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31. PubMedCrossRef
Polonsky KS. The past 200 years in diabetes. New Engl J Med. 2012;367(14):1332–40. PubMedCrossRef
Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141–6. PubMedPubMedCentral
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329(14):977–86. CrossRef
Keen H. The diabetes control and complications trial (DCCT). Health Trends. 1994;26(2):41–3. PubMed
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. New Engl J Med. 2003;348(23):2294–303. PubMedCrossRef
Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37. PubMed
Brogard JM, Vetter T, Blickle JF. Discovery of pancreatic diabetes in Strasbourg. Diabete Metabol. 1992;18(2):104–14.
Agarwal A, Brayman KL. Update on islet cell transplantation for type 1 diabetes. Semin Intervent Radiol. 2012;29(2):90–8. PubMedPubMedCentralCrossRef
Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16(1):35–9. PubMedCrossRef
Misler S. The isolated pancreatic islet as a micro-organ and its transplantation to cure diabetes: celebrating the legacy of Paul Lacy. Islets. 2010;2(4):210–24. PubMedPubMedCentralCrossRef
Reckard CR, Ziegler MM, Barker CF. Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery. 1973;74(1):91–9. PubMed
Shapiro AM. A historical perspective on experimental and clinical islet transplantation. Informa Health Care. 2007;1.
Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. 1999;8(3):285–92. PubMedCrossRef
Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes. 1989;38(Suppl 1):140–2. PubMedCrossRef
Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New Engl J Med. 2000;343(4):230–8. PubMedCrossRef
Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab. 2006;8(1):1–7. PubMedCrossRef
Scharp DW, Kemp CB, Knight MJ, Ballinger WF, Lacy PE. The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation. 1973;16(6):686–9. PubMedCrossRef
Najarian JS, Sutherland DE, Matas AJ, Steffes MW, Simmons RL, Goetz FC. Human islet transplantation: a preliminary report. Transpl Proc. 1977;9(1):233–6.
Brendel M HB, Shulz A, Bretzel R. International islet transplant registry report. 1999.1–20.
Benhamou PY, Watt PC, Mullen Y, Ingles S, Watanabe Y, Nomura Y, et al. Human islet isolation in 104 consecutive cases. Factors affecting isolation success. Transplantation. 1994;57(12):1804–10. PubMedCrossRef
Goto M, Eich TM, Felldin M, Foss A, Kallen R, Salmela K, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation. 2004;78(9):1367–75. PubMedCrossRef
Ihm SH, Matsumoto I, Sawada T, Nakano M, Zhang HJ, Ansite JD, et al. Effect of donor age on function of isolated human islets. Diabetes. 2006;55(5):1361–8. PubMedCrossRef
Lakey JR, Rajotte RV, Warnock GL, Kneteman NM. Human pancreas preservation prior to islet isolation. Cold ischemic tolerance. Transplantation. 1995;59(5):689–94. PubMedCrossRef
Lakey JR, Warnock GL, Rajotte RV, Suarez-Alamazor ME, Ao Z, Shapiro AM, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61(7):1047–53. PubMedCrossRef
Matsumoto I, Sawada T, Nakano M, Sakai T, Liu B, Ansite JD, et al. Improvement in islet yield from obese donors for human islet transplants. Transplantation. 2004;78(6):880–5. PubMedCrossRef
Nano R, Clissi B, Melzi R, Calori G, Maffi P, Antonioli B, et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia. 2005;48(5):906–12. PubMedCrossRef
Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57(6):954–8. PubMedCrossRef
Kin T, Murdoch TB, Shapiro AM, Lakey JR. Estimation of pancreas weight from donor variables. Cell Transplant. 2006;15(2):181–5. PubMedCrossRef
Brandhorst H, Brandhorst D, Hering BJ, Federlin K, Bretzel RG. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes. 1995;103(Suppl 2):23–6. PubMed
Berney T, Johnson PR. Donor pancreata: evolving approaches to organ allocation for whole pancreas versus islet transplantation. Transplantation. 2010;90(3):238–43. PubMedCrossRef
O’Gorman D, Kin T, Murdoch T, Richer B, McGhee-Wilson D, Ryan E, et al. The standardization of pancreatic donors for islet isolation. Transpl Proc. 2005;37(2):1309–10. CrossRef
de Boer J, De Meester J, Smits JM, Groenewoud AF, Bok A, van der Velde O, et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int. 1999;12(6):447–53. PubMedCrossRef
Hering BJ, Matsumoto I, Sawada T, Nakano M, Sakai T, Kandaswamy R, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation. 2002;74(12):1813–6. PubMedCrossRef
Benhamou PY, Oberholzer J, Toso C, Kessler L, Penfornis A, Bayle F, et al. Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999–2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d’Ilots de Langerhans. Diabetologia. 2001;44(7):859–64. PubMedCrossRef
Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation. 2002;74(12):1761–6. PubMedCrossRef
Wolters GH, Vos-Scheperkeuter GH, van Deijnen JH, van Schilfgaarde R. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. Diabetologia. 1992;35(8):735–42. PubMedCrossRef
Johnson PR, White SA, London NJ. Collagenase and human islet isolation. Cell Transplant. 1966;15(4):437–52.
Wang X, Meloche M, Verchere CB, Ou D, Mui A, Warnock GL. Improving islet engraftment by gene therapy. J Transplant. 2011;2011:594851. PubMedPubMedCentral
Mehigan DG, Bell WR, Zuidema GD, Eggleston JC, Cameron JL. Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg. 1980;191(3):287–93. PubMedPubMedCentralCrossRef
Lake SP, Bassett PD, Larkins A, Revell J, Walczak K, Chamberlain J, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(Suppl 1):143–5. PubMedCrossRef
Ichii HPA, Khan A, Fraker C, Ricordi C. Culture and transportation of human islets between centers. Islet transplantation and beta cell replacement therapy. New York: Informa healthcare; 2007. p. 251. CrossRef
Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830–5. PubMedCrossRef
Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8(6):1250–61. PubMedCrossRef
Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037–46. PubMedCrossRef
Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86(1):36–45. PubMedPubMedCentralCrossRef
Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83(1):24–8. PubMedCrossRef
Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;86(12):1658–65. PubMedPubMedCentralCrossRef
Rajab A. Islet transplantation: alternative sites. Curr Diab Rep. 2010;10(5):332–7. PubMedCrossRef
Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55–9. PubMedCrossRef
Barshes NR, Lee TC, Goodpastor SE, Balkrishnan R, Schock AP, Mote A, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005;200(3):353–61. PubMedCrossRef
Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002;51(1):66–72. PubMedCrossRef
Owen RJ, Ryan EA, O’Kelly K, Lakey JR, McCarthy MC, Paty BW, et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology. 2003;229(1):165–70. PubMedCrossRef
Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9. PubMedCrossRef
Gala-Lopez B, Pepper AR, Shapiro AM. Biologic agents in islet transplantation. Curr Diab Rep. 2013;13(5):713–22. PubMedCrossRef
Bloom SR, Polak JM. Somatostatin. Br Med J. 1987;295(6593):288–90. CrossRef
Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 2008;51(2):227–32. PubMedCrossRef
Shapiro AM. A historical perspective on experimental and clinical islet transplantation. In: Shapiro AM, Shaw JA, editors. Islet transplantation and beta cell replacement therapy. New York, London: Informa Healthcare; 2007. CrossRef
Gabardi S, Martin ST, Roberts KL, Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health-System Pharm: AJHP: Official J Am Soc Health-System Pharmacists. 2011;68(3):211–8. CrossRef
Hering BJ. Repurification: rescue rather than routine remedy. Am J Transplant. 2005;5(1):1–2. PubMedCrossRef
Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89(4):465–71. PubMedCrossRef
Matsumoto S, Takita M, Chaussabel D, Noguchi H, Shimoda M, Sugimoto K, et al. Improving efficacy of clinical islet transplantation with iodixanol based islet purification, Thymoglobulin induction and blockage of IL-1-beta and TNF-alpha. Cell Transplant. 2011;20(10):1641–7.
Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant. 2004;4(3):295–8. PubMedCrossRef
Xenos ES, Farney AC, Widmer MB, Casanova D, Stevens RB, Blazar BR, et al. Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans. Transpl Proc. 1992;24(6):2863–4.
Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant. 2005;5(9):2318–23. PubMedCrossRef
Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant. 2004;4(10):1709–12. PubMedCrossRef
The CITR Coordinating Center and Investigators. The collaborative islet transplant registry (CITR) 2011 seventh annual report. https://​web.​emmes.​com/​study/​isl/​reports/​01062012_​7thAnnualReport.​pdf. Accessed 27 Jan 2017.
Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35(7):1436–45. PubMedPubMedCentralCrossRef
Senior PA, Kin T, Shapiro AMJ, Koh A. Islet transplantation at the University of Alberta: status update and review of progress over the last decade. Can J Diabetes. 2012;36:32–7. CrossRef
Pepper AR, Gala-Lopez B, Ziff O, Shapiro AJ. Current status of clinical islet transplantation. World J Transplant. 2013;3(4):48–53. PubMedPubMedCentral
Senior PAKT, Shapiro AMJ, Koh A. Islet transplantation at the University of Alberta: Status update and review of progress over the last decade. Can J Diabetes. 2012;36:32–7. CrossRef
Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310(12):1240–7. PubMedCrossRef
Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant. 2011;16(6):627–31. PubMedPubMedCentralCrossRef
Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91(3):373–8. PubMedCrossRef
Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–62. PubMedCrossRef
Patrick AW, Campbell IW. Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes. Diabet Med. 1990;7(4):349–54. PubMedCrossRef
Gonder-Frederick LA, Clarke WL, Cox DJ. The Emotional, Social, and Behavioral Implications of Insulin-Induced Hypoglycemia. Semin Clin Neuropsychiatry. 1997;2(1):57–65. PubMed
Hathout E, Lakey J, Shapiro J. Islet transplant: an option for childhood diabetes? Arch Dis Child. 2003;88(7):591–4. PubMedPubMedCentralCrossRef

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions